Regeneron Pharmaceuticals Inc. closed $66.17 short of its 52-week high ($1,211.20), which the company reached on August 27th.

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly ...

The likely unification of Ireland will mean a greater economic role for the west but we need to plan for development like the ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Tectonic Therapeutic (TECX – Research Report) today. The company’s ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it ...

The Family and Medical Leave Act does not require employers to allow qualified employees to work remotely. While such ...

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

Dupilumab significantly reduced severe asthma exacerbations and SCS prescriptions vs omalizumab in patients using add-on maintenance therapy.